Alaunos Therapeutics, Inc. (TCRT) Free cash flow 2016–2025
Alaunos Therapeutics, Inc. (TCRT) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$3.0MFY2025 · since FY2016: -$58.9M → -$3.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$3.0M | +40.3% |
| FY2024 | -$5.0M | +83.6% |
| FY2023 | -$30.3M | -3.0% |
| FY2022 | -$29.4M | +54.5% |
| FY2021 | -$64.8M | +3.0% |
| FY2020 | -$66.8M | -62.4% |
| FY2019 | -$41.1M | +17.6% |
| FY2018 | -$49.9M | +9.9% |
| FY2017 | -$55.4M | +5.9% |
| FY2016 | -$58.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TCRT financial trends
TCRT RevenueTCRT Net incomeTCRT Net marginTCRT Gross profitTCRT Gross marginTCRT Operating incomeTCRT Operating marginTCRT Operating cash flowTCRT Capital expendituresTCRT Return on equityTCRT Stock buybacksTCRT Dividends paidTCRT Total assetsTCRT Total liabilitiesTCRT Shareholders’ equityTCRT overview →